Net sales now expected to range from $525.0 million to $550.0 million; adjusted EBITDA expected to range from $34.0 million to $37.0 million; free cash flow expected to be breakeven with capital spending at 2.5% of sales Revised adjusted EBITDA guidance at the mid-point represents approximately 12% growth year over year, down from approximately 15% per previous guidance.

The updated guidance reflects the expected favorable impact of the announced restructuring program, with restructuring charges to be excluded from adjusted EBITDA.